A high density of tumor-infiltrating mature dendritic cells (DC) and CD8
Introduction
Recent advances in tumor biology have highlighted the complex interplay between the immune system and tumor and have revealed the major role of the adaptive immune system in the control of tumor growth (1, 2) . The tumor microenvironment consists in a complex network of malignant, stromal, and immune cells. Tumor-infiltrating immune cells have been described in most solid tumors (3, 4) . The type, the density, and the location of immune cells in the tumor microenvironment, defined as immune contexture strongly affect the prognosis of cancer patients (4) (5) (6) (7) . In non-small cell lung cancer (NSCLC), a high density of mature dendritic cells (DC) correlates with long-term survival of the patients (8) and with a strong infiltration by CD8 þ T cells that are predominantly of the effector-memory phenotype (9) . Within the group of patients with high densities of CD8 þ T cells, those with few mature DCs exhibit lower overall survival (OS) than those with high densities of mature DCs, suggesting that tumor-infiltrating CD8 þ T cells may be functionally heterogenous (9, 10) . The immunogenicity of cancer cells results from their antigenicity, (i.e., the expression of specific tumor antigens) and their adjuvanticity, (i.e., the expression or release of dangerassociated molecular patterns or DAMP). One particular way to deliver DAMPs into the tumor microenvironment is immunogenic cell death (ICD), a functionally peculiar type of apoptosis that stimulates tumor-specific immune responses (11) (12) (13) (14) . The immunogenicity of cell death relies on at least three independent events, namely (i) the preapoptotic exposure of the endoplasmic reticulum (ER) chaperone protein calreticulin (CRT; refs. 15, 16) and perhaps other chaperones such as HSP70 and HSP90 (17) , at the cell surface, (ii) the subsequent autophagy-dependent active secretion of adenosine triphosphate (ATP; refs. 3, 18, 19) and (iii) the postapoptotic release of the nuclear nonhistone chromatin-binding protein high mobility group box 1 (HMGB1; refs. 20, 21) . By binding to CD91 on the surface of DCs, CRT functions as an "eat-me" signal, thus promoting the engulfment of apoptotic bodies by DCs (22) . Knockdown of CRT, blockade of ecto-CRT, or inhibition of the pathway leading to CRT exposure abolishes the immunogenicity of cell death (19, 23) . These findings suggest that DAMPs can stimulate antigen presenting cells, particularly DCs, to efficiently engulf dying cells, process antigens, mature, and induce an efficient immune response.
Most studies on ICD have focused on experimental mouse models (19, 20, (23) (24) (25) (26) (27) (28) and in vitro human studies (15, 17, 19, 20, (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) , but large-scale studies are necessary to determine the prognostic value of ICD-associated DAMPs expression, as well as their role in cancer immunosurveillance in patients. Here, we investigated the clinical impact of CRT expression on two independent cohorts of operable NSCLC patients having received neoadjuvant chemotherapy or not. Using IHC on operative specimen, we demonstrate that CRT is a powerful prognostic factor for OS of NSCLC patients, which were either treated by neoadjuvant chemotherapy or left without treatment, even after correcting for pathologic stage. Furthermore, we evaluated whether expression of CRT is associated with an enhanced cellular immune response. We identified a statistically significant correlation between expression of CRT and density of mature DCs, but not with CD8 þ T cells, B cells, and macrophages. We showed on fresh resected tumors that exposure of CRT occurs specifically at the cell surface of tumor cells and is strongly associated with the presence of effector memory T cells in the tumor microenvironment. 
Patients and Methods

IHC
In the study groups 1 and 2, tumor samples were fixed in neutral buffered 10% formalin solution and paraffin-embedded. For each paraffin-embedded lung tumor, two observers (M.-C. Dieu-Nosjean and D. Damotte) selected the tumor section containing a representative area of tumor with adjacent lung parenchyma, and the highest density of immune cells on the hematoxylin and eosin-safran-stained tissue section. CRT, P-eIF2a, CD8, Ki67, DC-LAMP, CD20, CD68, and MHC-I immunostaining were conducted as follows, using the avidinbiotin-peroxidase complex method. Paraffin section was dewaxed, followed by antigen retrieval with Target Retrieval Solution (Dako), 10 mmol citrate buffer at pH 6.0 (for CRT, MHC-I, and CD68), in TRIS EDTA pH 9 (for P-eIF2a) or pH 8 (for CD8/Ki-67 double labeling) in a preheated water bath (98 C, 30 minutes). Sections were cooled at room temperature for 30 minutes and endogenous peroxidase was blocked with 3% hydrogen peroxide. Thereafter, sections were incubated with diluted 5% human serum for 30 minutes and incubated with mouse anti-human CRT mAb (clone FMC75, Abcam, 5 mg/mL), rabbit anti-human P-eIF2a mAb (clone E90, Abcam, 5 mg/mL), mouse anti-human MHC-I (clone ab70328, Abcam, 1/7,000), mouse anti-human CD68 (clone PGM1, Dako, 0.6 mg/mL) for 2 hours at room temperature. Peroxidase-linked secondary antibodies (Dako) and AEC (3-amino-9-ethylcarbazole) or DAB (3, 3 0 -diaminobenzidine, Dako) were used to detect specific binding.
For CD8/Ki67 double labeling, slides were incubated rabbit anti-human CD8 (clone SP16, Spring Bioscience, 1/100) and mouse anti-human Ki67 (clone MIB-1, Dako, 0.35 mg/mL) for 2 hours at room temperature, followed by incubation with biotinylated donkey anti-rabbit and uncoupled goat anti-mouse (Jackson Immunoresearch), then by incubation with HRP-streptavidin (Dako, 2.6 mg/mL) and APAAP (phosphatase-anti-alkaline phosphatase, Dako, 3.48 mg/mL). AEC and alkaline phosphatase substrate (Vector laboratories) were used to detect specific staining.
CD8, DC-LAMP, and CD20 staining was performed as described previously (9, 36) . For CD8, double labeling with AE1/AE3 was performed.
Methods for cell quantification
The expression level of CRT and P-eIF2a for each patient was determined as the score of positive tumor cells. The quantification of DC-LAMP, CD8, CD20, and CD68 was performed as described previously (9, 36) . Images were acquired using Nanozoomer (Hamamatsu) operated with NDPview software; CD8 þ and DC-LAMP Immunofluorescence For the detection of CRT, the cells were placed on ice, washed twice with PBS, and fixed in 0.25% paraformaldehyde in PBS for 5 minutes. The cells were then washed twice in PBS, and a primary anti-CRT antibody (clone FMC75, Enzo) or isotype control and anti-Na
ATPase a1 antibody (Santa Cruz Biotechnology) diluted in cold blocking buffer was added for 30 minutes. After two washes in cold PBS, the cells were incubated for 30 minutes with the appropriate secondary antibody Alexa Fluor 488 IgG1 (Life Technologies) and Alexa Fluor 594 donkey anti-mouse IgG (HþL), respectively. The cells were fixed with 4% paraformaldehyde for 20 minutes, washed in PBS for 20 minutes, and mounted on slides.
Flow cytometry
Fresh lung tumor specimens and distant nontumoral tissues (taken at more than 10 cm of the tumor) were mechanically (manual) dissociated and digested in the presence of Cell Recovery Solution (BD Biosciences). Total live mononuclear cells were isolated from the tumors, as described previously (9), using Ficoll density-gradient separation. Briefly, cells from pellet remaining after Ficoll separation were incubated with primary antibodies against CD45, cytokeratin, human epithelial antigen, CD227 to distinguish the population of leukocytes, stromal, and epithelial cells, and antibodies against CRT (clone FMC75, Enzo) or isotype control, for 30 minutes at 4 C. Cells were washed and stained with Alexa 648-conjugated monoclonal secondary antibody for 30 minutes at 4 C. After washing, cell viability was assessed by AnnexinV PE (BD Pharmigen) or Live/Death Yellow staining (Life Technologies) and DAPI. For the characterization of immune cell population, mononuclear cells were stained with multiple panels of antibodies conjugated to fluorescent dyes and isotype controls (see Supplementary Table S1 ). Briefly, mononuclear cells were incubated with the primary antibodies for 30 minutes at 4 C in the dark. Cells were washed and analyzed on a LSRII cytometer (BD Biosciences) and FlowJo (TreeStar, Inc.) software.
Statistical analyses
Survival analysis was performed using the "survival" R package, using both log-rank tests and Cox proportional hazards regressions. When using a log-rank test, prognostic value of continuous variables was assessed using a median-based cutoff, or the optimal P value approach ( Supplementary Fig. S1 ). In the latter case, P values were corrected using the technique proposed by Altman and colleagues (37) . For Cox proportional hazards regressions, immune densities were log-transformed. In multivariate Cox regressions, variables that were not significantly associated with prognosis in univariate analysis (Wald test P > 0.05) were not included, as well as variables intrinsically correlated (for instance, continuous CRT variable was prioritized over dichotomized CRT). For linear correlation, orthogonal regression was used to plot the regression line, as noise is assumed to equally affect both CRT and P-eIF2a. Fisher exact test, Student t test, Wilcoxon, and Mann-Whitney tests were used to test for association between variables. Positive prognostic value conferred by tumoral CRT and P-eiF2a expression in NSCLC patients. Representative images showing low and high CRT expression in NSCLC tissue. A, CRT-positive cells are shown in red. B, boxplots representing the distributions of CRT score according to stages. Kaplan-Meier survival curves for OS for 270 patients with NSCLC without neoadjuvant chemotherapy according to the presence of a high or low expression of CRT evaluated using the optimal cut-off approach, P ¼ 1.7 Â 10 À14 (C), using median, P ¼ 8.17 Â 10 À9 (D) and using both CRT expression as well as stage stratification using the optimal cut-off approach, P ¼ 3.1 Â 10 À22 (E) and using median, P ¼ 1.23 Â 10 À18 (F). Representative images showing low and high P-eIF2a expression in NSCLC tissue.
G, P-eIF2a-positive cells are shown in red. Correlation graph for P-eIF2a and CRT expression on tumor cells in the cohort of NSCLC patients. H, the gray line was determined by orthogonal regression. Kaplan-Meier survival curves for OS for 164 NSCLC patients according to the presence of a high or low density of P-eIF2a evaluated using optimal cut-off approach, P ¼ 0.0011 (I) or using median, P ¼ 0.035 (J). P value was determined by log-rank test. Tables show the number of patients at risk in each group at several time points.
Results
Prognostic impact of CRT expression in NSCLC Tumor samples from a retrospective series of 270 patients with NSCLC (Table 1) , who did not receive neoadjuvant chemotherapy, were analyzed for CRT expression by IHC (Fig.  1A) . We observed a heterogeneous distribution of CRT expression among different patient's tumors, with a score ranging from grade 1 to 5 (1 for weak expression and 5 for strong expression). CRT was found both in the cytoplasm and at the surface of tumor cells (Fig. 1A) . We did not find a significant difference of CRT expression between TNM stages (Fig. 1B) . We divided the cohort into two groups, with high (CRT Hi ) and low (CRT Lo ) CRT expression on tumor cells, using the minimal P value approach (Fig. 1C) . Calculations of the optimal cutoff [stratifying according to the minimization of the P value of a log-rank test, which was corrected using the method published by Altman and colleagues (37) to control for multiple testing] set the limit of the expression score at 2.45 ( Supplementary Fig. S1A ). This approach revealed that low CRT expression was associated to poor prognosis (P ¼ 1.7 Â 10 À14 ) and allowed for the identification of a small group of patients with low CRT expression affected by a particularly short OS (Fig. 1C) 1D ). The median OS was 28 months for CRT Lo group and increased to 100 months for the CRT Hi group (Fig. 1D ). Kaplan-Meier survival curves were also significantly different across quartiles of CRT expression, revealing a dose-effect relationship (Supplementary Fig. S2 ; P ¼ 4.35 Â 10 À12 ).
These results define CRT expression as a strong predictive marker for OS of NSCLC patients. As CRT expression did not correlate with pathologic staging (Fig. 1B) , the current gold standard for lung cancer risk assessment, we investigated whether these two parameters are independently prognostic, by using a multivariate Cox model (Table  3) . CRT expression, pathologic staging, and age turned out to be the only significant predictors of OS. Kaplan-Meier curves combining stage and CRT stratifications using the optimal P value (Fig. 1E ) and median cutoffs (Fig. 1F) were consistent with this interpretation. CRT Hi /stage I patients had the best OS prognosis (median OS was 101 or 110 months using optimal or median cutoff, respectively). In contrast, patients in the pathologic stage III-IV and low expression of CRT were at the highest risk of death (median OS was 11 or 14 months using optimal or median stratification, respectively; Fig. 1E and F) . Of note, when the optimal cutoff for stratifying tumors into CRT Lo and CRT Hi is used, it appears that CRT Lo /stage I patients succumb more quickly than CRT Hi /stage III-IV patients (Fig. 1E ), suggesting that CRT low expression can identify patients with high risk of death even at early stages. Altogether, these data show that CRT expression and pathologic stage are independent prognostic factors.
We performed CRT quantification as well as survival analyzes in an independent cohort of 125 patients that were all affected by stage III NSCLC and treated with neoadjuvant chemotherapy (Supplementary Table S2 ). These patients received platinum salt-based chemotherapy in combination with gemcitabine (46%), vironelbine (34%), paclitaxel (14%), or anthracyclines (6%) before surgery. Again, expression of CRT using the optimal P value approach confirmed a strong prognostic impact of the CRT-based stratification (Supplementary Table S3 ). The comparison of CRT expression level by tumor cells between the two cohorts of patients revealed no differences ( Supplementary Fig. S4A ), indicating that the received neoadjuvant chemotherapy did not influence CRT expression.
Correlation between eIF2a phosphorylation and CRT expression in lung tumor cells
The translocation of CRT to the cell surface is triggered in response to an ER stress that involves the phosphorylation of the eukaryotic translation initiation factor eIF2a by PKR-like ER kinase (PERK; refs. 19, 23, 38) . Using IHC, we found that phosphorylated-eIF2a (P-eIF2a) was mostly expressed in NSCLC cells (as opposed to stromal elements), although with an interindividual variability, similarly to that found for CRT staining (Fig. 1G) . We observed a statistically significant correlation between the expression of P-eIF2a and CRT in the two cohorts of NSCLC patients that were either not treated (P ¼ 2.7 Â 10 À10 , r ¼ 0.46, Fig. 1H ) or treated with neoadjuvant chemotherapy (P ¼ 2.3 Â 10 À13 , r ¼ 0.70, Supplementary Fig.   S3E ). High P-eiF2a expression was correlated with longer survival using optimal cutoff (P ¼ 0.001; Fig. 1I and P ¼ 0.0033 Supplementary Fig. S3C , respectively for the cohorts of patients that were not treated and treated with neoadjuvant chemotherapy), and using median stratification (P ¼ 0.0035 Fig. 1J and P ¼ 0.0333 Supplementary Fig. S3D , respectively, for the cohorts of patients that were not treated and treated with neoadjuvant chemotherapy). We did not observe any difference in the distribution of P-eiF2a between untreated and neoadjuvant-treated patients ( Supplementary  Fig. S4B ), indicating that the neoadjuvant chemotherapy did not effect on P-eiF2a phosphorylation. For both cohorts, univariate Cox analysis revealed that CRT and P-eIF2a were significantly associated to OS (Table 2 and Supplementary Table S3 ). We analyzed the prognostic value of the two parameters using multivariate Cox proportional hazards regression (Table 3 and Supplementary Table S4) . P-eIF2a then lost its prognostic impact, which indicates that the strong correlation between the two variables prevents their concomitant use for risk assessment.
High expression of CRT is associated with an enhanced cellular immune response
CRT is best characterized for its prominent function as an eatme signal, leading to maturation of DCs and activation of adaptive immune responses against tumors (39) . Therefore, we addressed the impact of CRT expression on the density of tumor-infiltrating immune cells, including mature DCs (DC-LAMP þ cells, Fig. 2A ), CD8 þ T cells (Fig. 2B) , CD8/KI67 proliferating CD8 þ T cells, CD20 þ B cells, and CD68 þ macrophages (data not shown and Supplementary Fig. S5 ), in the cohort of untreated patients. The great majority of the samples contained rather low numbers of DC-LAMP þ cells, mainly found in the tumor stroma and associated with the tertiary lymphoid structures, as we previously reported (8) . Patients with high CRT expression exhibited significantly (P ¼ 0.042) higher densities of mature DCs (medians 1.1 and 0.6 cells/mm 2 for CRT Hi and CRT Lo groups respectively, Fig. 2A ). However, there was no significant difference in the CD8 þ T-cell density (P ¼ 0.15; Fig. 2B ), B-cell density (P ¼ 0.27), macrophage density (P ¼ 0.92; Supplementary Fig. S5A ), and in the number of CD8 þ /Ki67 þ proliferating T cells (P ¼ 0.29; Supplementary Fig. S5B ),
between CRT Hi and CRT Lo tumors. We also quantified the level of MHC-I expression by tumor cells and found that MHC-I expression was highly heterogeneous among patients. There was no difference in MHC-I expression between CRT Hi and CRT Lo tumors (P ¼ 0.7; Supplementary Fig. S5C ).
Confirming prior observations (9), high densities of DC-LAMP þ cells, and of CD8 þ T cells had a positive impact on patient survival ( Supplementary Fig. S6A and S6B). Univariate Cox 
, evaluated using the median cut-off approach. P value was determined by the log-rank test. Tables show the number of patients according to the expression of CRT and DC-LAMP or CD8 high and low groups. (Table 2) . We evaluated the combined prognostic value of CRT plus DC-LAMP or CD8, at the median cutoff ( Fig. 2C and D (Fig. 2D) . Similar results were obtained when using the optimal cutoff for CRT score ( Supplementary Fig. S6C and S6D) .
Using multivariate Cox analysis, the age, the pTNM stage, and the CRT score were found to be significantly and independently associated with OS, whereas mature DC and CD8 cell densities were not found significantly associated with OS (Table 3) . Altogether, these data demonstrate that CRT expression and mature DC or CD8 þ T-cell densities are not independent prognostic factors.
Cell surface exposure of CRT on primary tumor cells from NSCLC patients By using IHC, the exposure of CRT expression at the cell surface of tumor cells is not easily quantifiable. We performed flow cytometry analysis on freshly resected human NSCLC patients treated by primary surgery to characterize the expression of CRT (Fig. 3) . Surface CRT expression was detected in the population of AnnexinV (Fig. 3A) . Using an antibody against the leukocyte marker CD45 and a panel of antibodies specific for epithelial surface markers, we distinguished populations of leukocytes, stromal, and epithelial cells (Fig. 3B) . The percentage of CRT-positive cells was evaluated among these cells in both tumoral and distant nontumoral tissues ( Fig. 3C and  D) . Although highly heterogeneous, the expression of membrane CRT was significantly increased (P < 0.0001) on tumor epithelial cells as compared with epithelial cells from nontumoral tissues in the majority of patients (Fig. 3D) . Leukocytes and stromal cells from tumoral and nontumoral tissues did not express CRT on their surface (Fig. 3D ), although such cells did contain intracellular CRT, as revealed by immunofluorescence staining after plasma membrane permeabilization ( Supplementary Fig. S7 ) using a similar gating strategy. Confocal microscopy of epithelial tumor cells stained for ecto-CRT and the Na þ -K þ pump confirmed that CRT was indeed localized at the plasma membrane of the majority of the tumor cells (Fig. 3E) . Because the expression of CRT can strongly influence the population of immune cells, we evaluated the impact of membrane CRT expression by tumor cells, on the immune cell infiltrate with a focus on T lymphocytes and
þ , plasmacytoid DCs (pDC) and myeloid DCs (cDC; Fig. 4A 
Discussion
CRT has been evaluated as a potential biomarker in several types of cancer including neuroblastoma (40) , bladder (41), gastric (42) , breast cancer (43) , and acute myeloid leukemia (38) . CRT has also been reported to be overexpressed in the cytoplasm and at the membrane level of NSCLC cells, and serum level of CRT protein was associated with tumor pathologic grade (44) , although the prognostic impact of circulating CRT levels has not been studied. Here, we assessed the prognostic value of CRT expression in two independent retrospective cohorts of patients with NSCLC, one treated by primary surgery without neoadjuvant chemotherapy (n ¼ 270, stage I to III-IV) and the second one treated by neoadjuvant chemotherapy followed by surgery (n ¼ 125, stage III N2).
In NSCLC samples, we observed a major interindividual variability in CRT expression irrespective of the histologic subtype of NSCLC. Nevertheless CRT expression was not affected by the stage and Cox multivariate regression analyses confirmed that CRT expression and stage are two independent prognostic factors. High levels of CRT were associated with long survival of NSCLC patients. Our data are in accordance with findings in neuroblastoma (40) , in which high CRT correlates with neuroblastoma differentiation and favorable outcome. Conversely, in esophageal squamous cell carcinoma, CRT expression had no impact on patients' survival (32) , suggesting that CRT levels may only predict patient survival in some cancer types. In our study, CRT expression strongly correlated with the constitutive phosphorylation of eIF2a. This suggests that a subgroup of NSCLC is associated with a strong constitutive ER stress response that culminates in CRT expression and exposure, facilitating anticancer immunosurveillance. To date, the precise mechanisms that explain why some but not all NSCLCs are inclined to ER stress and others not remain to be elucidated. In breast cancer, changes in ploidy have been linked to the level of eIF2a phosphorylation and the intensity of the tumor infiltrate after anthracycline-based chemotherapy (45) . Whether similar mechanisms apply to NSCLC remains to be investigated.
We observed similar levels of CRT and P-eiF2a expression by tumor cells from patients that were left untreated or underwent neoadjuvant chemotherapy. Similar results were obtained in the prospective cohorts of patients, in which we demonstrated high expression of CRT at the cell surface of tumor cells in some patients. In addition, high CRT and P-eiF2a expression conferred a good clinical outcome in both cohorts. These results demonstrate that received chemotherapy is not the driver for high CRT expression or for CRT exposure at the cell surface, in www.aacrjournals.org Cancer Res; 76(7) April 1, 2016 (38) . When present at the surface of tumor cells, CRT can stimulate antigen-presenting cells, particularly DCs, to efficiently engulf dying cells, process their antigens and prime T-cell immune response (16, 19, 29) . Accordingly, a high density of mature DCs closely correlated with high expression of CRT in NSCLC. Previous reports demonstrated that high levels of ecto-CRT on tumor cells positively correlated with the activation of DCs and the capacity of DCs to stimulate IFNg by autologous T cells (17, 19, 29) . However, we did not observe a major positive correlation between the density of total CD8 þ T cells and CRT expression in NSCLC. In a cohort of prospective patients treated by primary surgery without neoadjuvant chemotherapy, we have observed significantly higher percentage of cDCs and effector memory CD4 þ and CD8 þ T cells in CRT high tumors than in CRT low NSCLCs, whereas the frequency of total CD4 þ and CD8 þ T cells was identical. These data are in accordance with results showing that the densities of infiltrating mature DC and effector-memory T cells correlate among each other (9) . These results demonstrate that high CRT expression at the cell surface of tumor cells leads to elevated frequency of mature DCs, and impact the quality of antitumor immune response, leading to the differentiation of tumor-infiltrating T cells towards an effector memory phenotype. Effectormemory T cells have been identified to control cancer progression.
Mainly the cytotoxic and cytokinic capability of effector memory T cells may provide them the relevant weapons to control tumor progression and metastatic invasion at the primary tumor site (46) . In numerous cancers, the presence of tumor-infiltrating effector memory T cells correlates with reduced metastatic invasion and increased survival of the patient (47) . When looking at other effectors of the immune response, we did not find any difference in the density of tumor-infiltrating B cells and macrophages. In addition, because CRT is an ER-chaperone molecule, its expression level might affect the loading of peptide on MHC-I, and hence the level of MHC-I expression at the cell surface. However, we did not find any difference in the expression level of MHC-I molecules on cancer cells from CRT Hi while that of CRT Lo tumors would be dysfunctional. In this case, one could speculate that in the absence of efficacious priming, the T-cell response is polyclonal and not efficient. However, this conjecture requires further experimental exploration.
In conclusion, high CRT expression, which is likely driven by an ER stress response, constitutes a positive prognostic biomarker in NSCLC patients. The available data are compatible with the hypothesis that the local presence of CRT, which is constitutively expressed at the surface of transformed epithelial cells, may enable DC-dependent anticancer immunosurveillance.
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